Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
View on Grants.gov ↗ Sign in to save
- Type
- Grant
- Notice type
- CA
- Agency
- National Institutes of Health
- Sub-agency
- HHS-NIH11
- Solicitation #
- PAR-25-226
- Posted
- Nov 22, 2024
- Response due
- Nov 19, 2026
- Archive date
- Dec 25, 2026
- CFDA / Assistance listing
- 93.242
- Contact
- grantsinfo@nih.gov
- Source
- Grants.gov
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.